

## Supplemental Tables

**Table S11.** Incidence rate (95% CI) and hazard ratios (95% CI) of atrial fibrillation in association with galectin-3 quartiles, ARIC, 1996 – 2013.

Atrial fibrillation	Galectin-3 (ng/ml)				P for trend
	Q1	Q2	Q3	Q4	
Events, n	264	289	253	379	-
Person-years	30522	30466	29321	28249	-
Incidence rate*	8.6 (7.7 – 9.8)	9.5 (8.4 – 10.6)	8.6 (7.6 – 9.8)	13.4 (12.1 – 14.8)	-
Model 1	1 (Referent)	1.08 (0.91 – 1.28)	1.00 (0.84 – 1.19)	1.55 (1.32 – 1.84)	< 0.0001
Model 2	1 (Referent)	1.05 (0.89 – 1.24)	0.91 (0.76 – 1.09)	1.24 (1.04 – 1.48)	0.02
Model 3	1 (Referent)	1.13 (0.95 – 1.35)	1.01 (0.83 – 1.24)	1.42 (1.14 – 1.77)	0.002
Model 4	1 (Referent)	1.06 (0.88 – 1.26)	0.94 (0.77 – 1.14)	1.23 (0.99 – 1.54)	0.05
<b>Model 5</b>	<b>1 (Referent)</b>	<b>1.06</b> <b>(0.88 – 1.26)</b>	<b>0.93</b> <b>(0.76 – 1.14)</b>	<b>1.23</b> <b>(0.99 – 1.54)</b>	<b>0.05</b>

\*Incidence rate is unadjusted and per 1,000 person-years.

Model 1: adjusted for age (continuous), race (white, black) and sex (female, male).

Model 2: Model 1 plus systolic blood pressure (continuous), blood pressure medications (yes, no), BMI (continuous), height (continuous), diabetes status (yes, no), total cholesterol (continuous), smoking status (current, former, never) and eGFR (continuous).

Model 3: Model 2 plus SNP rs4644 (AA, AC, CC).

Model 4: Model 3 plus ln NT-proBNP (continuous), ln CRP (continuous), and ln TnT (continuous).

**Model 5: Model 4 plus left atrial abnormality (yes, no).**

**Table S112.** Hazard ratios (95% CI) of atrial fibrillation in association with galectin-3 quartiles accounting for incident coronary disease and heart failure as time dependent variables, ARIC, 1996 – 2013.

	Galectin-3 (ng/ml)				P for trend
	Q1	Q2	Q3	Q4	
CHD*, n	155	134	153	202	-
Heart failure*, n	163	189	240	343	-
Hazard ratio <sup>†</sup>	1 (Referent)	1.056 (0.88 – 1.26)	0.88 (0.72 – 1.087)	1.0910 (0.88 – 1.367)	0.464

CHD: coronary heart disease.

\* Events occurred after onset of study but before diagnosis of atrial fibrillation

<sup>†</sup> Adjusting for age (continuous), race (white, black) and sex (female, male), systolic blood pressure (continuous), blood pressure medications (yes, no), BMI (continuous), height (continuous), diabetes status (yes, no), total cholesterol (continuous), smoking status (current, former, never). SNP rs4644 (AA, AC, CC), eGFR (continuous), ln NT-proBNP (continuous), ln CRP (continuous), and ln TnT (continuous), ~~and left atrial abnormality (yes, no).~~

**Table SIII.3.** Race-specific incidence rate (95% CI) and hazard ratios (95% CI) of atrial fibrillation in relation to *LGALS3* rs4644 genotype, ARIC, 1996 – 2013.

Characteristics	rs4644 genotype			P for trend
	CC	AC	AA	
<b>Whites</b>				
N (%)	2303 (34.6)	3209 (48.3)	1137 (17.1)	-
Mean (SD) Galectin-3 (ng/mL)	16.7 (3.9)	13.9 (3.2)	11.1 (2.5)	<0.0001
AF, n	352	469	196	-
Incidence rates* (95% CI)	10.9 (9.8 – 12.1)	10.4 (9.5 – 11.4)	12.3 (10.7 – 14.2)	-
Model 1	1 (Referent)	0.95 (0.82 – 1.09)	1.10 (0.92 – 1.31)	0.46
<b>Blacks</b>				
N (%)	939 (52.6)	714 (40.0)	134 (7.5)	-
Mean (SD) Galectin-3 (ng/mL)	17.3 (7.5)	14.2 (3.6)	11.6 (3.1)	<0.0001
AF, n	94	63	11	-
Incidence rates* (95% CI)	7.0 (5.7 – 8.6)	6.3 (4.9 – 8.1)	5.7 (3.1 – 10.3)	-
Model 1	1 (Referent)	0.88 (0.64 – 1.21)	0.75 (0.40 – 1.41)	0.28

AF: atrial fibrillation.

\*Unadjusted incidence rates and per 1,000 person-years.

Model 1: adjusted for age (continuous), and sex (female, male) and, in blacks, for 10 principal components of ancestry.